Skip to main content
. 2018 Dec 21;63(1):e01832-18. doi: 10.1128/AAC.01832-18

TABLE 1.

In vitro activity of sulopenem and comparator antimicrobial agents against E. coli isolated from urine specimens of Canadian patients from 2014 to 2016

E. coli phenotype (no. of isolates tested) and antimicrobial agent MIC data (µg/ml)
 MIC interpretation (%)
MIC50 MIC90 Range Susceptible Intermediate Resistant
All isolates (539)
    Sulopenem 0.03 0.03 0.015 to 0.12 NAa NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.12 100 0 0
    Ceftriaxone ≤0.25 1 ≤0.25 to >64 90.4 0.1 9.5
    Amoxicillin-clavulanate 4 16 0.5 to >32 81.3 14.6 4.1
    SXTb ≤0.12 >8 ≤0.12 to >8 75.5 NA 24.5
    Nitrofurantoin 16 16 ≤1 to 256 97.8 1.5 0.7
    Ciprofloxacin ≤0.06 >16 ≤0.06 to >16 76.3 0.1 23.6
    Gentamicin ≤0.5 1 ≤0.5 to >32 91.3 0.4 8.3
Pansusceptiblec isolates (309)
    Sulopenem 0.03 0.03 0.015 to 0.06 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.12 100 0 0
    Ceftriaxone ≤0.25 ≤0.25 ≤0.25 to 1 100 0 0
    Amoxicillin-clavulanate 4 8 0.5 to 8 100 0 0
    SXT ≤0.12 0.25 ≤0.12 to 2 100 NA 0
    Nitrofurantoin 16 16 2 to 32 100 0 0
    Ciprofloxacin ≤0.06 ≤0.06 ≤0.06 to 0.5 100 0 0
    Gentamicin ≤0.5 ≤0.5 ≤0.5 to 2 100 0 0
SXT-susceptible isolates (407)
    Sulopenem 0.03 0.03 0.015 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.12 100 0 0
    Ceftriaxone ≤0.25 ≤0.25 ≤0.25 to >64 94.3 0 5.7
    Amoxicillin-clavulanate 4 16 0.5 to >32 88.0 9.1 2.9
    SXT ≤0.12 0.25 ≤0.12 to 2 100 NA 0
    Nitrofurantoin 16 16 ≤1 to 128 98.3 1.2 0.5
    Ciprofloxacin ≤0.06 >16 ≤0.06 to >16 85.3 0 14.7
    Gentamicin ≤0.5 1 ≤0.5 to >32 95.1 0.5 4.4
SXT-nonsusceptible isolates (132)
    Sulopenem 0.03 0.06 0.015 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.06 100 0 0
    Ceftriaxone ≤0.25 >64 ≤0.25 to >64 78.0 0.8 21.2
    Amoxicillin-clavulanate 8 16 2 to >32 60.6 31.8 7.6
    SXT >8 >8 4 to >8 0 NA 100
    Nitrofurantoin 16 32 ≤1 to 256 96.2 2.3 1.5
    Ciprofloxacin 16 >16 ≤0.06 to >16 48.5 0.7 50.8
    Gentamicin ≤0.5 32 ≤0.5 to >32 79.5 0 20.5
Ciprofloxacin-susceptible isolates (411)
    Sulopenem 0.03 0.03 0.015 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.12 100 0 0
    Ceftriaxone ≤0.25 ≤0.25 ≤0.25 to >64 96.6 0.2 3.2
    Amoxicillin-clavulanate 4 16 0.5 to >32 86.9 10.2 2.9
    SXT ≤0.12 >8 ≤0.12 to >8 84.4 NA 15.6
    Nitrofurantoin 16 16 ≤1 to 128 99.8 0 0.2
    Ciprofloxacin ≤0.06 0.12 ≤0.06 to 1 100 0 0
    Gentamicin ≤0.5 1 ≤0.5 to >32 95.9 0.2 3.9
Ciprofloxacin-nonsusceptible isolates (128)
    Sulopenem 0.03 0.06 0.015 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.06 100 0 0
    Ceftriaxone ≤0.25 >64 ≤0.25 to >64 70.3 0 29.7
    Amoxicillin-clavulanate 8 16 1 to >32 63.3 28.9 7.8
    SXT >8 >8 ≤0.12 to >8 46.9 NA 53.1
    Nitrofurantoin 16 32 ≤1 to 256 91.4 6.3 2.3
    Ciprofloxacin >16 >16 2 to >16 0 0.8 99.2
    Gentamicin ≤0.5 >32 ≤0.5 to >32 76.6 0.7 22.7
SXT- and ciprofloxacin-susceptible isolates (347)d
    Sulopenem 0.03 0.03 0.015 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.12 100 0 0
    Ceftriaxone ≤0.25 ≤0.25 ≤0.25 to >64 97.7 0 2.3
    Amoxicillin-clavulanate 4 8 0.5 to >32 90.8 6.6 2.6
    SXT ≤0.12 ≤0.12 ≤0.12 to 2 100 NA 0
    Nitrofurantoin 16 16 ≤1 to 32 100 0 0
    Ciprofloxacin ≤0.06 ≤0.06 ≤0.06 to 0.5 100 0 0
    Gentamicin ≤0.5 1 ≤0.5 to >32 98.3 0.3 1.4
SXT- and ciprofloxacin-nonsusceptible isolates (68)d
    Sulopenem 0.03 0.06 0.015 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.06 100 0 0
    Ceftriaxone ≤0.25 >64 ≤0.25 to >64 66.2 0 33.8
    Amoxicillin-clavulanate 8 32 2 to >32 55.9 33.8 10.3
    SXT >8 >8 4 to >8 0 NA 100
    Nitrofurantoin 16 32 ≤1 to 256 94.1 4.4 1.5
    Ciprofloxacin >16 >16 2 to >16 0 1.5 98.5
    Gentamicin ≤0.5 >32 ≤0.5 to >32 76.5 0 23.5
MDRe isolates (71)
    Sulopenem 0.03 0.06 0.015 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.06 100 0 0
    Ceftriaxone 16 >64 ≤0.25 to >64 46.5 0 53.5
    Amoxicillin-clavulanate 16 32 4 to >32 32.4 50.7 16.9
    SXT >8 >8 ≤0.12 to >8 23.9 NA 76.1
    Nitrofurantoin 16 64 2 to 256 87.3 8.5 4.2
    Ciprofloxacin >16 >16 ≤0.06 to >16 11.3 0 88.7
    Gentamicin 1 >32 ≤0.5 to >32 56.3 1.4 42.3
ESBL-negative isolates (490)
    Sulopenem 0.03 0.03 0.03 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.12 100 0 0
    Ceftriaxone ≤0.25 ≤0.25 ≤0.25 to >64 99.2 0 0.8
    Amoxicillin-clavulanate 4 16 0.5 to >32 83.9 12.8 3.3
    SXT ≤0.12 >8 ≤0.12 to >8 78.8 NA 21.2
    Nitrofurantoin 16 16 ≤1 to 256 98.2 1.4 0.4
    Ciprofloxacin ≤0.06 >16 ≤0.06 to >16 81.4 0.2 18.4
    Gentamicin ≤0.5 1 ≤0.5 to >32 93.7 0 6.3
ESBL-positive isolates (49)
    Sulopenem 0.03 0.06 0.03 to 0.12 NA NA NA
    Meropenem ≤0.03 ≤0.03 ≤0.03 to 0.06 100 0 0
    Ceftriaxone >64 >64 1 to >64 2.0 2.1 95.9
    Amoxicillin-clavulanate 8 32 4 to >32 55.1 32.7 12.2
    SXT >8 >8 ≤0.12 to >8 42.9 NA 57.1
    Nitrofurantoin 16 16 2 to 256 93.9 2.0 4.1
    Ciprofloxacin >16 >16 ≤0.06 to >16 24.5 0 75.5
    Gentamicin ≤0.5 >32 ≤0.5 to >32 67.3 4.1 28.6
AmpC-positive isolates (4)
    Sulopenem NA NA 0.03 to 0.12 NA NA NA
    Meropenem NA NA ≤0.03 to 0.06 100 0 0
    Ceftriaxone NA NA ≤0.25 to >64 25.0 0 75.0
    Amoxicillin-clavulanate NA NA 32 to >32 0 0 100
    SXT NA NA 0.25 to >8 50.0 NA 50.0
    Nitrofurantoin NA NA 8 to 32 100 0 0
    Ciprofloxacin NA NA ≤0.06 to >16 50.0 0 50.0
    Gentamicin NA NA ≤0.5 to 1 100 0 0
a

NA, there are no MIC breakpoints defined for this antimicrobial agent or no intermediate MIC breakpoint for this antimicrobial agent, or there were <30 isolates tested and an MIC50 and MIC90 could not be generated.

b

SXT, trimethoprim-sulfamethoxazole.

c

Pansusceptible isolates were susceptible to meropenem, ceftriaxone, amoxicillin-clavulanate, SXT, nitrofurantoin, ciprofloxacin, and gentamicin and excluded MDR isolates and isolates resistant to one (n = 89) and two (n = 70) of the aforementioned list of antimicrobial agents.

d

There were 124 isolates of E. coli that were SXT susceptible and ciprofloxacin nonsusceptible or SXT nonsusceptible and ciprofloxacin susceptible that were excluded from this analysis.

e

MDR was defined as nonsusceptible to ≥3 agents from different antimicrobial classes (ceftriaxone, amoxicillin-clavulanate, SXT, nitrofurantoin, ciprofloxacin, and gentamicin). The most common MDR phenotypes were isolates nonsusceptible to amoxicillin-clavulanate, ciprofloxacin, and SXT (n = 13; 18.3% of MDR isolates); isolates nonsusceptible to ceftriaxone, ciprofloxacin, and SXT (n = 9; 12.7% of MDR isolates); isolates nonsusceptible to amoxicillin-clavulanate, ceftriaxone, ciprofloxacin, and SXT (n = 7; 9.9% of MDR isolates); isolates nonsusceptible to ciprofloxacin, SXT, and gentamicin (n = 6; 8.5% of MDR isolates); isolates nonsusceptible to amoxicillin-clavulanate, ceftriaxone, and ciprofloxacin (n = 4; 5.6% of MDR isolates); and isolates nonsusceptible to amoxicillin-clavulanate, ciprofloxacin, SXT, and gentamicin (n = 4; 5.6% of MDR isolates).